Forces that defy diabetic macular edema treatment

Article

Despite the promise of emerging anti-VEGF therapies for improving control of clinically significant diabetic macular edema, not all patients respond.

Despite the promise of emerging anti-VEGF therapies for improving control of clinically significant diabetic macular edema (DME), not all patients respond. Others who benefit initially can develop recurrent clinically significant DME. In these cases, confounding factors can include treatment with alternative agents or controlling sleep apnea, according to Jay Haynie, OD.

But agents that confound anti-VEGF therapy include thiazolidinedione oral antidiabetic agents such as pioglitazone (Actos, Takeda Pharmaceuticals North America Inc.) and rosiglitazone (Avandia, GlaxoSmithKline), Dr. Haynie said.

"Sleep apnea is more common than most clinicians realize, and therefore, widely underdiagnosed," he said. "In our practice, we've been amazed by how many of our treatment-refractory DME patients are discovered to be suffering from sleep apnea as well as by how their macular health improves after they begin treatment for their sleep disorder." The figures above illustrate OCT scans before and after sleep apnea therapy in one patient.

Over a 20-month period, eight patients with clinically significant DME were referred for sleep study tests after demonstrating resistance to anti-VEGF therapy, Dr. Haynie said. All were diagnosed with sleep apnea varying from mild to severe. All eight patients began CPAP treatment for their obstructive sleep disorder, and the macular edema significantly lessened or resolved within 8 months in six of the eight patients.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Jessilin Quint, OD, MBA, FAAO, outlines her AOA's Optometry's Meeting 2025 presentation on nutrition and its impact on ocular health.
Carolyn Majcher, OD, FAAO, detailed a talk she gave alongside Mary Beth Yackey, OD, at Optometry's Meeting 2025.
Shelby Brogdon, OD, details opportunities for practices to answer the patient's concerns from the chair before they hit the internet for their contact lens needs.
Christi Closson, OD, FAAO, shares her excitement for the new Acuvue Oasys MAX 1-Day multifocal for astigmatism
Karen R. Hoffman, OD, shares how customizable scleral lenses can transform vision for patients with complex corneas, achieving 20/20 outcomes and enhanced comfort.
Janna Pham, OD, shares key takeaways from a corneal tomography session she presented alongside Travis Pfeifer, OD; and Matthew McGee, OD.
Jacob Lang, OD, FAAO, details early symptom relief demonstrated in as early as day 1 during AOA's Optometry's Meeting 2025.
When Langis Michaud, OD, MSc, FAAO, FSLS, FBCLA, FEAOO, began fitting scleral lenses 20 years ago, there was limited knowledge about conjunctival characteristics, scleral shape, and lens behavior.
Ioussifova details what sets Johnson & Johnson's new lens apart from the rest, which was launched at the American Optometric Association's Optometry's Meeting 2025.
Alongside Rachel Steele, OD, Rafieetary outlines what to look for in blurred disc margins and the importance of acting fast and sending patients to the ED when needed.
© 2025 MJH Life Sciences

All rights reserved.